Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Bruce Lefroy Centre, |
RCV001072144 | SCV001235710 | likely pathogenic | Intellectual disability, autosomal dominant 6 | 2020-01-01 | criteria provided, single submitter | research | PM1, PM2, PM6, PP2 |
Labcorp Genetics |
RCV001862473 | SCV002228735 | pathogenic | Intellectual disability, autosomal dominant 6; Developmental and epileptic encephalopathy, 27 | 2024-02-24 | criteria provided, single submitter | clinical testing | This sequence change replaces leucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 813 of the GRIN2B protein (p.Leu813Val). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with clinical features of GRIN2B-related conditions (PMID: 33604570; Invitae). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 864861). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GRIN2B protein function with a positive predictive value of 95%. For these reasons, this variant has been classified as Pathogenic. |